Exploring Cardiff Oncology, Inc. (CRDF) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in Cardiff Oncology, Inc. (CRDF) and what's driving their decisions? With a market cap of approximately $145.78 million as of April 2025, CRDF has caught the eye of various investor types. Is it the potential breakthrough in KRAS-mutated cancer treatments, highlighted by their clinical trials, or perhaps the strategic collaborations aimed at expanding their therapeutic pipeline? Dive in to uncover the dynamics of CRDF's investor landscape, from institutional giants holding significant stakes to individual investors betting on future growth, and understand the blend of factors influencing their investment strategies in the ever-evolving oncology market.

Cardiff Oncology, Inc. (CRDF) Who Invests in [Company Name] and Why?

Understanding the investor profile of Cardiff Oncology, Inc. (CRDF) provides valuable insights into market sentiment and potential drivers of stock performance. A diverse investor base can offer stability, while concentrated ownership may lead to higher volatility. Here's a breakdown of who's investing in Cardiff Oncology, and the motivations behind those investments. Also, you can check Mission Statement, Vision, & Core Values of Cardiff Oncology, Inc. (CRDF).

Key Investor Types:

Cardiff Oncology's shareholder base comprises a mix of individual investors, institutions, and hedge funds.

• Individual Investors: These investors hold the largest stake in Cardiff Oncology, with approximately 56% of the shares. This significant ownership suggests that key company decisions could be influenced by the broader public.
• Institutional Investors: Institutions hold a substantial portion of Cardiff Oncology's stock. Recent data indicates they hold approximately 34% of the company's shares. Institutional investors include mutual funds, pension funds, and other large entities. Top institutional shareholders include Commodore Capital LP, BlackRock, Inc., Pfizer Inc, and Vanguard Group Inc..
• Hedge Funds: Hedge funds also have a presence in Cardiff Oncology, with approximately 8.1% of shares controlled by hedge funds. Commodore Capital LP is the largest shareholder, holding 8.1% of the outstanding shares. Hedge funds are often active investors who seek to influence management and drive short- to medium-term value creation.

Investment Motivations:

Investors are drawn to Cardiff Oncology for a variety of reasons, largely centered on the company's potential for growth and innovation in the oncology space.

• Growth Prospects: Cardiff Oncology is a clinical-stage biotechnology company focused on developing novel cancer therapies. Its lead drug candidate, Onvansertib, is a PLK1 inhibitor being evaluated in clinical programs targeting RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer and triple negative breast cancer. Positive Phase II results for Onvansertib in first-line treatment of RAS-mutated cancers have strengthened investor confidence.
• Market Position: The company's focus on RAS-mutated cancers, which are often aggressive and difficult to treat, gives it a unique market position. Onvansertib's mutation-agnostic approach offers a potential advantage over therapies that target specific mutations.
• Financial Stability: A $40 million investment from biotech specialist investors has strengthened Cardiff Oncology's balance sheet, enabling further clinical development of Onvansertib.

Investment Strategies:

The diverse investor base employs various strategies when investing in Cardiff Oncology.

• Long-Term Holding: Many institutional investors, such as Vanguard and BlackRock, typically adopt a long-term holding strategy, reflecting confidence in the company's long-term potential.
• Short-Term Trading: Hedge funds often engage in short-term trading strategies, aiming to capitalize on stock price fluctuations and drive value creation in the short to medium term.
• Value Investing: Some investors may see Cardiff Oncology as undervalued, considering its potential growth and market position. Analyst price targets reflect this optimism, with an average one-year price target of $15.25, with forecasts ranging from $10.00 to $20.00.

Here's a summary of Cardiff Oncology's major shareholders:

Understanding the composition and motivations of Cardiff Oncology's investor base is crucial for assessing the company's market dynamics and potential future performance.

Cardiff Oncology, Inc. (CRDF) Institutional Ownership and Major Shareholders of Cardiff Oncology, Inc. (CRDF)

Institutional ownership in Cardiff Oncology, Inc. (CRDF) provides insights into the stability and investor confidence in the company. Examining which institutions hold significant shares, and any changes to those holdings, can offer a glimpse into market sentiment and potential future stock performance. You might also be interested in reading about Cardiff Oncology, Inc. (CRDF): History, Ownership, Mission, How It Works & Makes Money: Cardiff Oncology, Inc. (CRDF): History, Ownership, Mission, How It Works & Makes Money

As of March 31, 2024, Cardiff Oncology, Inc. had an institutional ownership of 57.46%. A breakdown of the top institutional holders provides further detail.

Here's a list of the top institutional investors in Cardiff Oncology, Inc. (CRDF) and their holdings:

• Vanguard Group Inc: Holding 4,898,282 shares
• BlackRock Inc.: Holding 4,394,484 shares
• RA Capital Management, L.P.: Holding 3,539,723 shares
• State Street Corp: Holding 1,792,230 shares
• FMR LLC: Holding 1,489,502 shares
• Geode Capital Management, LLC: Holding 819,890 shares
• Baker Bros. Advisors LP: Holding 739,712 shares
• Susquehanna International Group, LLP: Holding 514,873 shares
• Citadel Advisors LLC: Holding 447,238 shares
• Millennium Management LLC: Holding 442,519 shares

Reviewing recent changes in ownership can reveal shifts in institutional sentiment:

• During the first quarter of 2024, RA Capital Management, L.P. increased its holdings by 144%.
• Vanguard Group Inc. increased its holdings by ~6% in the first quarter of 2024.
• BlackRock Inc. increased its holdings by ~1% in the first quarter of 2024.

Institutional investors often play a significant role in a company's stock price and strategic direction. Their actions can drive trading volume and influence market perception. For a company like Cardiff Oncology, Inc. (CRDF), which is focused on clinical-stage oncology, institutional backing can be particularly crucial, providing financial stability and potentially influencing the company's ability to fund research and development activities.

The following table summarizes the institutional ownership details:

Cardiff Oncology, Inc. (CRDF) Key Investors and Their Impact on Cardiff Oncology, Inc. (CRDF)

Understanding the investor profile of Cardiff Oncology, Inc. (CRDF) provides critical insights into the company's stability, growth potential, and strategic direction. Key investors can significantly influence company decisions and stock performance through their holdings and actions.

While specific, up-to-the-minute details on all major investors and their recent moves in Cardiff Oncology, Inc. (CRDF) might require real-time financial data services, examining publicly available information and recent news can offer a general overview. Institutional investors, venture capital firms specializing in biotechnology, and strategic partners are likely to hold significant positions. Keep in mind that investor holdings can change frequently.

Here are potential types of investors and their possible impact:

• Institutional Investors: These may include mutual funds, pension funds, and hedge funds. Their investment decisions are often driven by detailed financial analysis and can significantly impact stock prices. For instance, a large institutional investor increasing their stake could signal confidence in Cardiff Oncology, Inc. (CRDF)'s prospects, potentially driving up the stock price.
• Venture Capital Firms: Biotech-focused VC firms often invest in companies like Cardiff Oncology, Inc. (CRDF) during early stages. Their expertise and funding can be crucial for drug development and clinical trials.
• Strategic Partners: Pharmaceutical companies might take equity stakes in Cardiff Oncology, Inc. (CRDF) to collaborate on drug development or secure future licensing agreements. These investments often come with substantial resources and industry expertise.
• Activist Investors: While not always present, activist investors could take a stake in Cardiff Oncology, Inc. (CRDF) and push for changes in corporate strategy or governance to unlock shareholder value.

To illustrate potential investor influence and recent moves, consider the following hypothetical scenarios:

Keep an eye on major financial news outlets and SEC filings (such as 13F filings) to track notable investor activity. These sources provide information on significant changes in ownership, which can offer clues about investor sentiment and future expectations for Cardiff Oncology, Inc. (CRDF).

For additional insights into Cardiff Oncology, Inc. (CRDF)'s values and goals, explore their Mission Statement, Vision, & Core Values of Cardiff Oncology, Inc. (CRDF).

Cardiff Oncology, Inc. (CRDF) Market Impact and Investor Sentiment

Investor interest and market perception significantly influence Cardiff Oncology, Inc. (CRDF). Examining investor sentiment, recent market reactions, and analyst perspectives provides a comprehensive view of the company's current standing and potential future.

Investor Sentiment:

Currently, the overall investor sentiment for Cardiff Oncology is very positive. According to data from top investing forums, the company has a sentiment score of 100 out of 100, indicating overwhelmingly positive discussions around the stock. This positive sentiment reflects confidence in the company's direction and potential.

A deeper dive into the ownership structure reveals:

• 56% of Cardiff Oncology is held by individual investors, giving the general public substantial influence over key policy decisions.
• 34% is held by institutions, indicating a significant level of credibility within the investment community.
• Hedge funds control approximately 8.1% of shares, suggesting active investor interest in driving short to medium-term value creation.

Major shareholders include:

• Commodore Capital LP with 8.1% of shares outstanding
• BlackRock, Inc.
• Pfizer Inc
• Vanguard Group Inc
• Orbimed Advisors LLC

Recent Market Reactions:

Recent market reactions to Cardiff Oncology's announcements have been mixed. For instance, after the Q4 2024 earnings report, the stock experienced an 8.97% decline during regular trading hours, closing at $4.46. However, it rebounded by 2.71% in after-hours trading, reaching $4.17. This volatility indicates a cautious investor sentiment, possibly influenced by the company's financial results and clinical trial outcomes.

Despite these short-term fluctuations, the stock has shown impressive returns over longer periods. InvestingPro data indicates returns of 150.56% over the past year and 90.6% over the last six months, though it also suggests the stock might be slightly overvalued at current levels.

On April 16, 2025, the stock's market cap touched US$186 million. Following a 15% increase in the stock price the previous week, individual investors and institutions both profited significantly.

As of April 15, 2025, the share price of Cardiff Oncology, Inc. was $2.94 per share, a 3.72% increase from the prior week. The market cap as of April 14, 2025, was $164.32 million.

Analyst Perspectives:

Analysts are generally bullish on Cardiff Oncology, with a consensus rating of 'Strong Buy'. This is based on ratings from several Wall Street analysts. The average analyst price target in the past three months is $15.25.

Specific analyst ratings include:

• Lucid Capital Markets initiated coverage with a 'Buy' rating and a price target of $14.00.
• H.C. Wainwright analyst Raghuram Selvaraju raised the price target to $17.00 from $13.00, maintaining a 'Buy' rating.

The potential upside based on analysts' average price target is significant. The average price target of $15.25 represents a 435.09% increase from the current price of $2.85. The highest price target is $20.00, while the lowest is $10.00.

Recent analyst recommendations show a strong buy trend. Based on 7 analysts, the overall rating for Cardiff Oncology is a 'Strong Buy'.

Analysts' twelve-month price targets for Cardiff Oncology average $11.67, with a high forecast of $17.00 and a low forecast of $8.00. This average price target represents a forecasted upside of 313.71% from the current price of $2.82.

Financial Stability and Cash Runway:

Cardiff Oncology's financial position is considered healthy, with more cash than debt on its balance sheet. The company completed a $40 million capital raise, bolstering its cash reserves. As of December 31, 2024, Cardiff Oncology had $91.7 million in cash and short-term investments. The company's cash runway is projected to extend into the first quarter of 2027.

Despite these strengths, InvestingPro analysis indicates that the company is quickly burning through cash, with a negative free cash flow yield of -19% over the last twelve months. However, Lucid Capital Markets estimates that the company's cash could fund operations into Q1 2027.

For more detailed information on Cardiff Oncology, Inc.'s background, mission, and ownership, you can visit: Cardiff Oncology, Inc. (CRDF): History, Ownership, Mission, How It Works & Makes Money